Endoscopy 2012; 44(06): 631
DOI: 10.1055/s-0032-1308948
Letters to the editor
© Georg Thieme Verlag KG Stuttgart · New York

Multimodal endoscopic therapy for multifocal intraepithelial neoplasia and superficial esophageal squamous cell carcinoma

V. Becker
,
A. Meining
Further Information

Publication History

Publication Date:
25 May 2012 (online)

Preview

We recently reported a series of six consecutive patients receiving endoscopic therapy for superficial esophageal squamous cell carcinoma (SESCC) [1]. Local endoscopic resection and radiofrequency ablation (RFA) were combined in a multimodal approach. Complete tumor eradication was achieved during follow-up ranging from 10 to 28 months.

Since that report, continuous follow-up examinations including Lugol-based chromoendoscopy have been performed twice annually. It is of interest that in three out of the six treated patients, synchronous SESCCs have been detected after 20, 24, and 30 months. All the neoplastic areas were distant from the previous lesion. There was no local tumor recurrence. Because of unchanged patient preferences, lesions were again treated, successfully, with the previously mentioned multimodal endoscopic approach.

In contrast to Barrett’s esophagus, where metaplastic epithelium is also ablated as it is the basis for neoplasia, we suspect that for squamous epithelium oncogenetic abnormalities persist after ablation (in addition to the patient risk factors). Our experience stands in agreement with published data reporting synchronous SESCC in up to 30 % of patients treated previously by endoscopic resection [2]. In contrast, data on neoplastic Barrett’s esophagus show complete eradication after either endoscopic resection or endoscopic resection followed by RFA in only one of 50 patients after 24 months [3].

In our opinion, RFA-based therapy of SESCC is still an option because further sessions can be successfully performed in patients with recurrent lesions. However, our limited data including patients with longer follow-up intervals demonstrate that the risk of metachronuous lesions is relatively high and close endoscopic follow-up examinations including Lugol staining, at 6-month intervals, appear mandatory.